Rate My Professor Amish Raval

Amish N. Raval, MD, serves as Professor in the Division of Cardiovascular Medicine within the Department of Medicine and holds an affiliate appointment as Professor in the Department of Biomedical Engineering at the University of Wisconsin-Madison. He was named to an Endowed Professorship in Cardiovascular Medicine. Dr. Raval earned his MD from the University of Western Ontario in London, Ontario, Canada. He completed residency in Internal Medicine and fellowship in Cardiovascular Medicine at the University of Western Ontario London Health Sciences Centre, followed by an Interventional Cardiology/Endovascular Medicine Fellowship at Georgetown University in Washington, D.C., and Intramural Post-Doctoral Fellowship in Interventional MRI, Cardiac and Peripheral Interventions, and Regenerative Medicine at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland.

Dr. Raval is a senior interventional cardiologist and translational clinician-scientist with over two decades at UW-Madison, directing Clinical Cardiovascular Research, the UW Heart Attack Program, and chairing the Cardiovascular Regenerative Medicine Focus Group. He also serves as Medical Director of the UW Health ST Elevation Myocardial Infarction program. His research specializes in cardiovascular regenerative medicine, developing interventional imaging platforms and biologic delivery systems using stem cells, gene transfer agents, and extracellular matrices for ischemic heart disease, heart failure, myocardial infarction, cardiomyopathy, and peripheral artery disease. He has led as national principal investigator in clinical trials including CardiAMP Heart Failure Phase III and SCRIPT-CLI, pioneered cardiac fibroblast-derived matrices enhancing stem cell retention, and advanced multi-modality 3D image fusion for transendocardial injections. Funded by NIH R01 and U01 grants, Wisconsin Alumni Research Foundation, and industry, he holds patents and has authored over 100 peer-reviewed publications, such as "Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency" (Int J Cardiol, 2021), "Cultured cardiac fibroblasts and myofibroblasts express Sushi Containing Domain 2" (Exp Cell Res, 2021), and AHA statements on right-sided heart failure (2018). Board-certified in internal medicine, cardiovascular diseases, and interventional cardiology, he belongs to the Society for Cardiac Angiography and Intervention, American College of Cardiology, and American Heart Association.